American Heart Association

sacubitril/valsartan

Rat Model Suggests Sacubitril/Valsartan may be Effective in Pulmonary Hypertension

Contributor: Ike Chinyere

Study Link: Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan

By |March 4th, 2020|basic science, Ike Chinyere, Pulmonary Hypertension, sacubitril/valsartan, Visual Abstract|0 Comments
Read More

Visual Abstract: Factors Associated with Persistently Low Sacubitril/Valsartan Use

Contributors: Ike Chinyere and Steven Stroud

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

Study Link: Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

By |January 17th, 2019|Ike Chinyere, sacubitril/valsartan, Steven Stroud, Visual Abstract|0 Comments
Read More

Low Adoption Rates of Sacubitril/Valsartan Use in the US

Contributor: Nick Hawkes

Sacubitril/valsartan reduces morbidity and mortality in patients with HFrEF, so why has the adoption of this therapy in the outpatient setting been so slow?

By |November 14th, 2018|Entresto, HFrEF, Nicholas Hawkes, sacubitril/valsartan|0 Comments
Read More

Sacubitril/Valsartan improves quality of life in patients with HFrEF

Contributor: Nicholas Hawkes

Quality not quantity. Why not both? It is established that sacubitril/valsartan is superior to enalapril (or dose-equivalent ACE-I) when it comes to mortality and morbidity in HFrEF. But what about quality of life (QoL)? Patients enrolled in PARADIGM-HF had increased quality of life when randomized to sacubitril/valsartan.

By |February 13th, 2018|HFrEF, Nicholas Hawkes, PARADIGM-HF, quality of life, sacubitril/valsartan|0 Comments
Read More